Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | YM-024 |
Synonyms | |
Therapy Description |
YM-024 inhibits PIK3CA and PIK3CD, which may block activation of the PI3K signaling pathway and inhibit tumor cell proliferation (PMID: 19815551). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
YM-024 | PIK3CA inhibitor 24 PIK3CD inhibitor 27 | YM-024 inhibits PIK3CA and PIK3CD, which may block activation of the PI3K signaling pathway and inhibit tumor cell proliferation (PMID: 19815551). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
PIK3CA over exp | glioblastoma | sensitive | YM-024 | Preclinical | Actionable | In a preclinical study, YM-024 inhibited proliferation and anchorage-independent growth of glioblastoma cell lines with elevated Pik3ca protein level in culture (PMID: 24718026). | 24718026 |
PIK3CA V344G | glioblastoma | no benefit | YM-024 | Preclinical | Actionable | In a preclinical study, YM-024 did not inhibit proliferation of glioblastoma cell lines harboring PIK3CA V344G in culture (PMID: 24718026). | 24718026 |
PIK3CA H1047Y | glioblastoma | sensitive | YM-024 | Preclinical | Actionable | In a preclinical study, glioblastoma cell lines harboring PIK3CA H1047Y demonstrated increased sensitivity to YM-024 induced growth inhibition (PMID: 24718026). | 24718026 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|